Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Tables)

v3.19.3
Composition of Certain Financial Statement Captions (Tables)
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Certain Financial Statement Captions
(In thousands)
September 30,
2019
 
December 31,
2018
Accounts receivable, net:
 
 
 
Accounts receivable
$
142,605

 
$
145,665

Less: allowance for doubtful accounts
(1,840
)
 
(1,758
)
 
$
140,765

 
$
143,907

Inventories, net:
 
 
 
Consumable supplies
$
23,022

 
$
23,264

Finished products
22,137

 
15,259

Work in-process
3,239

 
2,473

Raw materials
4,264

 
4,259

Less: inventory reserve
(2,553
)
 
(2,956
)
 
$
50,109

 
$
42,299

Other current assets and prepaid expenses:
 
 
 
Taxes recoverable
19,705

 
15,708

Other receivables
194

 
2,368

Prepaid supplies
8,915

 
9,693

Prepaid insurance
5,160

 
3,436

Other
3,327

 
3,847

 
$
37,301

 
$
35,052

Intangible assets, net:
 
 
 
Customer relationships
$
444,524

 
$
446,296

Technologies
340,539

 
340,729

Trade names
49,779

 
50,404

Licenses
5,766

 
5,766

Covenants not to compete
16,314

 
16,322

Product registrations
7,554

 
7,861

Other
5,974

 
5,613

Less: accumulated amortization
(306,140
)
 
(258,539
)
 
$
564,310

 
$
614,452

Accrued expenses:
 
 
 
Contract liabilities
$
30,951

 
$
63,503

Employee benefits
34,138

 
45,621

Clinical trials
9,975

 
10,401

Contingent consideration
2,375

 
2,375

Finance leases short-term
2,983

 
3,280

Milestone payment
5,000

 
4,871

Professional fees
2,877

 
7,935

Other
84,435

 
65,527

 
$
172,734

 
$
203,513

 
 
 
 

(In thousands)
September 30,
2019
 
December 31,
2018
Other long-term liabilities:
 
 
 
Contract liabilities
$
3,257

 
$
27,566

Line of credit
50,644

 
105,198

Contingent consideration
22,084

 
22,162

Mortgages and other debts payable
4,091

 
4,654

Finance leases long-term
4,325

 
5,620

Other
27,558

 
33,768

 
$
111,959

 
$
198,968


Changes in Goodwill
The following table summarizes the changes in Goodwill during the nine months ended September 30, 2019.
 
2019
(In thousands)
Balance at January 1
 
Foreign exchange and other
 
Balance at September 30th
Pharmaceuticals
 
 
 
 
 
CURNA
$
4,827

 
$

 
$
4,827

EirGen
85,245

 
(3,933
)
 
81,312

FineTech

 

 

OPKO Chile
4,614

 
(212
)
 
4,402

OPKO Biologics
139,784

 

 
139,784

OPKO Health Europe
7,546

 
(348
)
 
7,198

OPKO Renal
2,069

 

 
2,069

Transition Therapeutics
3,322

 
98

 
3,420

 
 
 
 
 
 
Diagnostics
 
 
 
 
 
BioReference
401,821

 

 
401,821

OPKO Diagnostics
17,977

 

 
17,977

OPKO Lab
32,988

 

 
32,988

 
$
700,193

 
$
(4,395
)
 
$
695,798